 rebamipide is a quinolone derivative that has been commonly used for the treatment of gastric and duodenal ulcers. It has also been shown to be effective in treating ulcerative colitis, an inflammatory bowel disease characterized by chronic inflammation of the large intestine. This study investigates the mechanism behind this effect, finding that rebamipide reduces inflammation and oxidative stress in the colon, which are both key drivers of ulcerative colitis. Rebamipide does so by activating the S-I-R-T-1-slash-Fox-O-3-A-slash-N-R-F-2 axis, which increases production of the anti-inflammatory protein P-paragamma, and inhibiting the P-I-3-K-slash-A-K-T pathway, which decreases inflammation and oxidative stress. This article was authored by Maha M. Abdelfada, M-Mod H. M. Hassanine, Ahmed M. Syed and others.